MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study

Authors: van Leeuwen-Stok, E., van Leeuwen, L., de Graaf, H., van Riel, J.M.G.H., Houtsma, D., Vrijaldenhoven, S., van der Velden, A.W.G., Peerdeman, A.L., van den Brink - Schimmel, R.J., Drooger, J.C., Imholz, A.L.Th., Dercksen, M.W., Oulad Hadj, J., Bakker, S.D., van der Wouw, A.J., Kerver, E.D., Bouma, G., van Schaik, C., de Boer, M., Mandigers, C.M.P.W., Koornstra, R.H.T., Smals, A., Rietbroek, R.C., van der Padt - Pruijsten, A., den Boer, M.O., Bos, H., Schiphorst, P.P.J.B.M., Vriens, B.E.P.J., van Rossum, Q.C., Tol, J., Hoogwerf - Kluft, D., Kruijtzer - Schimmel, C.M.F., Oosterkamp, H.M., Baas, I.O., Dietvorst, A.H.P., Davidis - van Schoonhoven, M., van Dijk, M.A., van der Voort, Anna, Louis, Fleur M, van Ramshorst, Mette S, Kessels, Rob, Mandjes, Ingrid A, Kemper, Inge, Agterof, Mariette J, van der Steeg, Wim A, Heijns, Joan B, van Bekkum, Marlies L, Siemerink, Ester J, Kuijer, Philomeen M, Scholten, Astrid, Wesseling, Jelle, Vrancken Peeters, Marie-Jeanne T F D, Mann, Ritse M, Sonke, Gabe S ^*

Source: In The Lancet Oncology May 2024 25(5):603-613

Biotransformation of Trastuzumab and Pertuzumab in Breast Cancer Patients Assessed by Affinity Enrichment and Ion-Exchange Chromatography

Authors: Olaleye, Oladapo ¹, Spanov, Baubek ¹, Bults, Peter ², van der Voort, Anna ³, Govorukhina, Natalia ¹, Sonke, Gabe S. ³, Horvatovich, Peter ¹, van de Merbel, Nico C. ^{1, 2}, Bischoff, Rainer ^{1, *}

Source: In Drug Metabolism and Disposition February 2023 51(2):249-256

Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival

Authors: van der Voort, Anna, Liefaard, Marte C., van Ramshorst, Mette S., van Werkhoven, Erik, Sanders, Joyce, Wesseling, Jelle, Scholten, Astrid, Vrancken Peeters, Marie Jeanne T.F.D., de Munck, Linda, Siesling, Sabine, Sonke, Gabe S.

Source: In The Breast October 2022 65:110-115

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Authors: van Ramshorst, Mette S, van der Voort, Anna, van Werkhoven, Erik D, Mandjes, Ingrid A, Kemper, Inge, Dezentjé, Vincent O, Oving, Irma M, Honkoop, Aafke H, Tick, Lidwine W, van de Wouw, Agnes J, Mandigers, Caroline M, van Warmerdam, Laurence J, Wesseling, Jelle, Vrancken Peeters, Marie-Jeanne T, Linn, Sabine C, Sonke, Gabe S ^*

Source: In The Lancet Oncology December 2018 19(12):1630-1640

Analytical and pharmacological consequences of the in vivo deamidation of trastuzumab and pertuzumab.

Authors: Bults, Peter^1,2 (AUTHOR), van der Voort, Anna³ (AUTHOR), Meijer, Coby⁴ (AUTHOR), Sonke, Gabe S.³ (AUTHOR), Bischoff, Rainer¹ (AUTHOR), van de Merbel, Nico C.^1,2 (AUTHOR) n.c.van.de.merbel@rug.nl

Source: Analytical & Bioanalytical Chemistry. Feb2022, Vol. 414 Issue 4, p1513-1524. 12p.

Subject Terms: *DEAMINATION, *BINDING site assay, *TRASTUZUMAB, *LIQUID chromatography-mass spectrometry, *BLOOD proteins, *DIGESTION

Correction: Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer.

Authors: van der Voort, Anna¹ (AUTHOR) a.vd.voort@nki.nl, van der Hoogt, Kay J. J.^2,3 (AUTHOR), Wessels, Ronni² (AUTHOR), Schipper, Robert-Jan^2,4 (AUTHOR), Wesseling, Jelle⁵ (AUTHOR), Sonke, Gabe S.^1,6 (AUTHOR), Mann, Ritse M.^2,7 (AUTHOR)

Source: European Radiology. Apr2025, Vol. 35 Issue 4, p2357-2357. 1p.

Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer.

Authors: van der Voort, Anna¹ (AUTHOR) a.vd.voort@nki.nl, van der Hoogt, Kay J. J.^2,3 (AUTHOR), Wessels, Ronni (AUTHOR), Schipper, Robert-Jan^2,4 (AUTHOR), Wesseling, Jelle (AUTHOR), Sonke, Gabe S.^1,5 (AUTHOR), Mann, Ritse M.^2,6 (AUTHOR)

Source: European Radiology. Jul2024, p1-11.

Subject Terms: *HER2 positive breast cancer, *DIFFUSION magnetic resonance imaging, *CONTRAST-enhanced magnetic resonance imaging, *HORMONE receptor positive breast cancer, *PATHOLOGIC complete response, *FISHER exact test

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.

Authors: van der Voort, Anna, van Ramshorst, Mette S., van Werkhoven, Erik D., Mandjes, Ingrid A., Kemper, Inge, Vulink, Annelie J., Oving, Irma M., Honkoop, Aafke H., Tick, Lidwine W., van de Wouw, Agnes J., Mandigers, Caroline M., van Warmerdam, Laurence J., Wesseling, Jelle, Vrancken Peeters, Marie-Jeanne T., Linn, Sabine C., Sonke, Gabe S.

Source: JAMA Oncology; Jul2021, Vol. 7 Issue 7, p978-984, 7p

Possible missed opportunities for diagnosing colorectal cancer in Dutch primary care: a multimethods approach

Authors: Brandenbarg, Daan, Groenhof, Feikje, Siewers, Ilse M., van der Voort, Anna, Walter, Fiona M., Berendsen, Annette J.

Source: British journal of general practice. 68(666):23-23

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN613902869&indx=1&recIds=ETOCRN613902869

This result is not displayed to guests.
Login for full access.